Dr. Gurbani received his Ph.D in biotechnology from the Council of Scientific & Industrial Research (CSIR) -Institute of Toxicology Research, Lucknow and Jamia Hamdard University, New Delhi, India, with an emphasis on molecular mechanism of quinone-based DNA damage and repair. His work demonstrated quinone inhibition of ATPase domain movement during the catalytic cycle of topoisomerase IIα resulting in inhibition of DNA repair and loss of genomic integrity, which may result in clastogenicity and leukemia.

During his postdoctoral training (2012-2018) in Westover Lab, part of the Department of Radiation Oncology at UT Southwestern, Dr. Gurbani led experimental efforts toward the development of several reversible and irreversible inhibitors for different cancer-associated kinases serving as useful pharmacological probes. During this period, Dr. Gurbani also completed coursework in clinical pharmacology and drug development.

Dr. Gurbani was promoted to Instructor on February 1, 2019. With his expertise in X-ray crystallography, biochemistry, cancer biology, and structure-guided drug development, Dr. Deepak continues to develop lead compounds targeting other cancer-associated kinases for development of new targeted cancer therapies.

Research Interest

  • Cancer therapeutics: developing kinase inhibitors
  • Developing RAS inhibitors
  • DNA damage and repair
  • Protein: structure and function


Featured Publications LegendFeatured Publications

Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine.
Du G, Rao S, Gurbani D, Henning NJ, Jiang J, Che J, Yang A, Ficarro SB, Marto JA, Aguirre AJ, Sorger PK, Westover KD, Zhang T, Gray NS, J. Med. Chem. 2020 Jan
Structure and Characterization of a Covalent Inhibitor of Src Kinase.
Gurbani D, Du G, Henning NJ, Rao S, Bera AK, Zhang T, Gray NS, Westover KD, Front Mol Biosci 2020 7 81
A highly selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase.
Scarneo SA, Hughes PF, Yang KW, Carlson DA, Gurbani D, Westover KD, Haystead TAJ, J. Biol. Chem. 2019 Dec
Structural basis of the atypical activation mechanism of KRAS V14I.
Bera AK, Lu J, Wales TE, Gondi S, Gurbani D, Nelson A, Engen JR, Westover KD, J. Biol. Chem. 2019 Jul
Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.
Rao S, Gurbani D, Du G, Everley RA, Browne CM, Chaikuad A, Li T, Schröder M, Gondi S, Ficarro SB, Sim T, Kim ND, Berberich MJ, Knapp S, Marto JA, Westover KD, Sorger PK, Gray NS, Cell Chem Biol 2019 Mar
Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-a Inhibition for Cancer and Autoimmune Disease.
Totzke J, Gurbani D, Raphemot R, Hughes PF, Bodoor K, Carlson DA, Loiselle DR, Bera AK, Eibschutz LS, Perkins MM, Eubanks AL, Campbell PL, Fox DA, Westover KD, Haystead TAJ, Derbyshire ER Cell Chem Biol 2017 Aug 24 8 1029-1039.e7
MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlates with poor prognosis.
Yang Y, Ding L, Hu Q, Xia J, Sun J, Wang X, Xiong H, Gurbani D, Li L, Liu Y, Liu A Mol. Cancer 2017 08 16 1 141
Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.
Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G, Nonami A, Griffin JD, Lauffenburger DA, Westover KD, Sorger PK, Gray NS Bioorg. Med. Chem. 2017 02 25 4 1320-1328
Structure-guided development of covalent TAK1 inhibitors.
Tan L, Gurbani D, Weisberg EL, Hunter JC, Li L, Jones DS, Ficarro SB, Mowafy S, Tam CP, Rao S, Du G, Griffin JD, Sorger PK, Marto JA, Westover KD, Gray NS Bioorg. Med. Chem. 2017 02 25 3 838-846
Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine.
Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer WD, Liu Y, Li L, Marto JA, Westover KD J. Biol. Chem. 2017 Jan 292 1 112-120

Honors & Awards

  • PDA Travel Award, UT Southwestern Medical Center, Dallas, Texas, US
  • RCB-Young Investigator (RCB-YI) Award, Regional Centre for Biotechnology, India
  • International Travel Award, Department of Science & Technology, India
  • International Travel Award, Department of Science & Technology, India
  • Junior Research Fellowship in Life Sciences, Council of Scientific and Industrial Research, India
  • Junior Research Fellowship, Indian Council of Medical Research, India
  • Lectureship Award in Life Sciences, University Grants Commission, India

Professional Associations/Affiliations

  • American Association for Cancer Research (2017)
  • American Association for the Advancement of Science (2017)
  • American Cancer Society Cancer Action Network (2017)
  • Radiation Research Society (2014)
  • Indian Nanoscience Society (2007)